{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:46:28Z","timestamp":1789386388854,"version":"build-2803163510"},"reference-count":8,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.jocn.2013.04.021","type":"journal-article","created":{"date-parts":[[2013,9,20]],"date-time":"2013-09-20T00:45:58Z","timestamp":1379637958000},"page":"507-508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Rasagiline induced hypersexuality in Parkinson\u2019s disease"],"prefix":"10.1016","volume":"21","author":[{"given":"Dennys","family":"Reyes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Kurako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestor","family":"Galvez-Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2013.04.021_b0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-2007-1017459","article-title":"Hypersexuality-a complication of dopaminergic therapy in Parkinson\u2019s disease","volume":"16","author":"Vogel","year":"1983","journal-title":"Pharmacopsychiatria"},{"key":"10.1016\/j.jocn.2013.04.021_b0010","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S1353-8020(09)70847-8","article-title":"Impulse control disorders in Parkinson\u2019s disease: definition, epidemiology, risk factors, neurobiology and management","volume":"15","author":"Ceravolo","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jocn.2013.04.021_b0015","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I","article-title":"Pathologic gambling in Parkinson\u2019s disease: a behavioral manifestation of pharmacologic treatment?","volume":"15","author":"Molina","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2013.04.021_b0020","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1212\/01.wnl.0000218206.20920.4d","article-title":"Prospective prevalence of pathologic gambling and medication association in Parkinson disease","volume":"66","author":"Voon","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2013.04.021_b0025","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archneur.63.7.969","article-title":"Association of dopamine agonist use with impulse control disorders in Parkinson disease","volume":"63","author":"Weintraub","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2013.04.021_b0030","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1517\/14740338.2011.573784","article-title":"Safety of rasagiline for the treatment of Parkinson\u2019s disease","volume":"10","author":"Perez-Lloret","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jocn.2013.04.021_b0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF01246955","article-title":"The possible mechanisms of action of (-)deprenyl in Parkinson\u2019s disease","volume":"43","author":"Knoll","year":"1978","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jocn.2013.04.021_b0040","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0896-6273(00)00113-6","article-title":"Toward a neurobiology of obsessive-compulsive disorder","volume":"28","author":"Graybiel","year":"2000","journal-title":"Neuron"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586813003238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586813003238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T18:21:56Z","timestamp":1539368516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586813003238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0967586813003238"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2013.04.021","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rasagiline induced hypersexuality in Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2013.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}